The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated×4•Originally published 16 April 2026•Updated 17 April 2026•

1 min read

Surge in Public Offerings Led by Madison Air and Healthcare Sector

Key Facts

1Madison Air announced the pricing of its $2.23 billion IPO at $27.00 per share.

about 2 months ago

Version History

Version 4about 2 months ago

What changed: Updated with specific pricing details for Trevi Therapeutics ($13.00/share), share volume, the underwriter over-allotment option, and the expected closing date.

Version 3about 2 months ago

What changed: The story was updated to include the IPO pricing and Nasdaq listing details for Kailera Therapeutics.

Version 2about 2 months ago

What changed: The story was updated to include Trevi Therapeutics' announcement of a new $150 million public offering.

Version 1about 2 months ago

What changed: Updated the story to reflect the successful closing of Spyre Therapeutics' offering with increased total proceeds of $463.5 million following the full exercise of the over-allotment option.

Financial markets are maintaining strong momentum in capital-raising activities, highlighted by Trevi Therapeutics pricing its public offering of 11,600,000 shares at $13.00 per share. The company granted underwriters a 30-day option for an additional 1,740,000 shares, with the offering expected to close on April 20, 2026, to fund its Haduvio™ chronic cough therapy. This follows Kailera Therapeutics' recent Nasdaq listing at $16.00 per share, aimed at advancing obesity treatments. The broader healthcare surge includes Spyre Therapeutics' $463.5 million raise and Madison Air’s dominant $2.23 billion offering. Additionally, firms like Allogene Therapeutics and HeartBeam continue to tap into market liquidity, signaling robust investor appetite for clinical-stage biotech developments.